Last Updated on October 10, 2024 by The Health Master
Drug recall:
Drug recall: Hospira, Inc., a Pfizer company, is voluntarily recalling the lots listed in the table below of 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10mL vial; 1% Lidocaine HCl Injection, USP, 50 mg/5mL vial; and 2% Lidocaine HCl Injection, USP, 100 mg/5mL vial to the user level.
The drug recall was initiated due to the potential for presence of glass particulate matter.
There is an unlikely probability for serious adverse events, including death, should a patient receive an injectable product found to contain particulate matter identified as glass.
Potential complications related to injection of visible and subvisible inert particles include inflammation of a vein, granuloma, and blockage of blood vessels or life-threatening blood clot events.
The frequency and severity of these adverse events could vary depending upon a variety of factors including the size and number of particles in the drug product, patient comorbidities (such as age, compromised organ function), and presence or absence of vascular anomalies.
The risk is reduced by the possibility of detection, as the label contains a clear statement directing the healthcare professional to visually inspect the product for particulate matter and discoloration prior to administration.
To date, Hospira, Inc. has not received reports of any adverse events associated with this issue for these lots.
Drug recall: Sodium Bicarbonate Injection
Sodium Bicarbonate Injection, USP is a sterile, nonpyrogenic, hypertonic solution of sodium bicarbonate (NaHCO3) in water for injection for administration by the intravenous route as an electrolyte replenisher and systemic alkalizer.
It is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis.
Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products.
It is also indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate.
Drug recall: Lidocaine Hydrochloride Injection
Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution of an antiarrhythmic agent administered intravenously by either direct injection or continuous infusion.
It is available in various concentrations. It is administered intravenously or intramuscularly and is specifically indicated in the acute management of ventricular arrhythmias such as those occurring in relation to acute myocardial infarction, or during cardiac manipulation, such as cardiac surgery.
The NDC, Lot Number, Expiration Date, and Configuration details for the impacted products are indicated below. The products were distributed nationwide to wholesalers/hospitals/institutions in the United States and Puerto Rico from October 13, 2022 through October 26, 2022.
| Product | NDC | Lot Number | Expiration Date | Presentation | Configuration/ Count |
|---|---|---|---|---|---|
| 4.2% Sodium Bicarbonate Injection, USP Glass ABBOJECT® Syringe | Carton 0409-5534-24 Case 0409-5534-14 | GJ5007 | 1AUG2024 | 5 mEq/10mL, (0.5 mEq/mL) | 1 vial and injector/ carton 10 cartons/ bundle Case pack 5 X 10- 10mL |
| 1% Lidocaine HCl Injection, USP LIFESHIELD® Glass ABBOJECT® Syringe | Carton 0409-4904-11 Case 0409-4904-34 | 42290DK | 1JUN2024 | 50 mg/5mL (10 mg/mL) | 1 vial and injector/ carton 10 cartons/ bundle Case pack 5 X 10- 5mL |
| 2% Lidocaine HCl Injection, USP LIFESHIELD® Glass ABBOJECT® Syringe | Carton 0409-4903-11 Case 0409-4903-34 | GH6567 | 1JUL2024 | 100 mg/5mL (20 mg/mL) | 1 vial and injector/ carton 10 cartons/ bundle Case pack 5 X 10- 5mL |
This drug recall is being executed with the knowledge of the U.S. Food and Drug Administration (USFDA).
Drug recall: Sun Pharma, Aurobindo recall these drugs due to this reason
Drug recall: Ibrexafungerp tablets recalled due to cross contamination
Drug Recall: Sucralfate Oral Suspension recalled due to this reason
Drug recall: WEFUN Capsules recalled due to presence of undeclared Sildenafil
Drug recall: Novartis recalled Cyclosporine oral solution
USFDA Approved Weight Loss Drugs: A Comprehensive Guide
IPC: Indian Pharmacopoeia Commission joins the Pharmacopoeial Discussion Group
USFDA issues Form 483 with one observation to Aurobindo Unit IV: Andhra Pradesh
Pakistan: New technology introduced for instant detection of spurious drugs
Weight Loss Medicines: Understanding Risks and Benefits
October 10: National GMP Day – A Turning Point
Antimicrobial Resistance: National Action Plan for NAP 2.0
Importance of Humidity Control in Pharmaceutical Industry
Drug recall: Sun Pharma, Aurobindo recall these drugs due to this reason
USFDA Drug Approval Process: A Comprehensive Guide
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
